Summary & Overview
HCPCS C1815: Implantable Urinary Sphincter Prosthesis
HCPCS Level II code C1815 identifies an implantable urinary sphincter prosthesis used to treat urinary incontinence from sphincter dysfunction. The code is nationally relevant because implantable urinary sphincter devices are a durable therapeutic option for patients with significant stress urinary incontinence or neurogenic sphincter insufficiency, and billing clarity affects hospital and ambulatory surgical center revenue cycles and patient access.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the device, expected sites of service, and common billing practices. The publication presents benchmark considerations for coverage and reimbursement, typical claim-line components, and policy-related issues that influence prior authorization and medical necessity determinations. It also summarizes typical modifiers and payer interactions where available.
This national summary is intended to help coding professionals, hospital billing staff, and policy analysts understand the clinical purpose of C1815, where the procedure is typically performed, and which major payers commonly appear in claim activity. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code C1815 denotes a prosthesis, urinary sphincter (implantable). This code represents the implanted device used to restore continence in patients with urinary sphincter dysfunction.
Service type: Implantation of an indwelling urinary sphincter prosthesis, including device placement procedures.
Typical site of service: Hospital operating room or ambulatory surgical center where implantable urologic prosthesis procedures are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult male with moderate-to-severe stress urinary incontinence following radical prostatectomy who has failed conservative measures (pelvic floor therapy, pads, or bulking agents) and is evaluated for an implantable urinary sphincter. Preoperative assessment includes urodynamic testing, cystoscopy, and counseling regarding device mechanism, risks, and expected continence outcomes. The implantable urinary sphincter is placed in an operating room under general or regional anesthesia; the procedure is typically performed by a urologist with experience in male continence surgery. Postoperative workflow includes activity restrictions, device activation in clinic (usually 4–6 weeks post-op), wound checks, and long-term follow-up for device function, infection, erosion, or mechanical failure. Hospital admission is uncommon; typical site of service is an ambulatory surgery center or hospital outpatient operating room when performed as a planned elective implant, or inpatient if concomitant procedures or medical comorbidities require monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the work, time, or intensity of the implant procedure substantially exceeds the usual service. |
23 |